Search

Anxiety and depressive symptoms affect up to 80% of people with chronic obstructive pulmonary disease (COPD). To reduce this symptom burden, clinicians should target modifiable explanatory factors while accounting for nonmodifiable explanatory factors of these symptoms. The purpose of this secondary data analysis was to examine which modifiable factors explain anxiety and depressive symptoms in COPD. This secondary data analysis of 1,760 COPD patients used multiple regression to explain anxiety and depressive symptoms from sets of modifiable patient characteristics and demographic controls. Clinically significant symptoms of anxiety or depression presented in 29.6% (n = 526) of participants, and 20.6% (n = 363) had both. Significant modifiable explanatory factors of both disorder symptoms were perceived functional status, functional capacity, psychosocial impact, symptom self-management, and significant symptoms for the other. Somatic symptom burden and dyspnea explained anxiety and depressive symptoms, respectively. Addressing these modifiable factors may reduce anxiety and depressive symptoms in patients with COPD. [ABSTRACT FROM AUTHOR]

Capgras syndrome (CS) is a type of delusional misidentification syndrome where an individual is under the impression that a person they know has been switched with an identical imposter. One theory for the development of CS is a disturbance among the frontal, limbic, and temporal areas, which creates an alteration in an individual's ability to recognize a person's face and provoke a response emotionally. The primary risk factors for the development of CS include having a neurological disorder and a diagnosis of schizophrenia. We present a case of a 39-year-old male with a past medical history of traumatic brain injury and familial history of schizophrenia who presented to the Emergency Department with paranoia and the belief that his father had been switched with an imposter. After ruling out organic causes, he was stabilized on olanzapine before discharge to outpatient follow-up. This case highlights the importance of prompt recognition of the symptomatology associated with CS and treatment with olanzapine for a favorable outcome., Competing Interests: Human subjects: Consent was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work., (Copyright © 2024, Gramling et al.)